The downstream manufacturing process takes the output from upstream operations and transforms it through multiple steps into a viable drug product ready for administration to patients. The major challenge in downstream processing is to maximize yield while meeting both product and impurity specifications. Viral vectors destined for clinical use must comply with regulatory standards for product safety and potency and this means contaminants must be removed and impurities controlled. This paper identifies challenges and opportunities to improve current operations and maximize yield.
©2020 Cell Culture Dish. All Rights Reserved. www.cellculturedish.com